The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer

Table 3 Clinicopathologic correlation of MMP-9 and TN-C status in 103 pancreatic cancer

	MMP-9			TN-C			fTN-C			MMP-9 + TN-C
	-	+	P	-	+	P	-	+	P	-	+	P
Gender			0.480			0.066			0.573			0.096
Male	29	38		35	32		50	17		43	24
Female	13	23		12	24		25	11		17	19
Age, years			0.416			0.588			0.582			0.692
<65	32	42		35	39		55	19		44	30
≥65	10	19		12	17		20	9		16	13
Tumor location			0.229			0.636			0.227			0.676
Head	38	50		41	47		66	22		52	36
Body/tail	4	11		6	9		9	6		8	7
Tumor size, cm			0.032			0.305			0.738			0.06
≤2	18	14		17	15		24	8		23	9
>2	24	47		30	41		51	20		37	34
Lymphatic invasion			0.019			0.021			0.008			<0.001
Negative	31	31		34	28		51	11		45	17
Positive	11	30		13	28		24	17		15	26
Vascular invasion			0.049			0.024			0.015			0.003
Negative	32	35		36	31		54	13		46	21
Positive	10	26		11	25		21	15		14	22
Hepatic metastases			0.009			0.003			0.003			<0.001
Negative	41	49		46	44		70	20		59	31
Positive	1	12		1	12		5	8		1	12
Differentiation			0.077			0.146			0.429			0.034
Poor	7	20		8	19		18	9		10	17
Moderate	29	38		34	33		49	18		44	23
Well	6	3		5	4		8	1		6	3
T-factor (UICC)			0.021			0.137			0.035			0.043
T1	11	6		12	5		15	2		14	3
T2	16	15		13	18		25	6		20	11
T3	14	37		21	30		34	17		25	26
T4	1	3		1	3		1	3		1	3
Stage (UICC)			0.019			0.012			0.005			<0.001
1A	7	2		8	1		9	0		9	0
1B	12	8		9	11		19	1		15	5
2A	10	16		15	11		19	7		19	7
2B	10	22		12	20		22	12		14	18
3	1	1		1	1		2	0		1	1
4	2	12		2	12		6	8		2	12

The bold values indicate P-values less than 0.05, UICC Union for International Cancer Control

ISSN: 1746-1596